NasdaqGM:TMDXMedical Equipment
A Look At TransMedics Group (TMDX) Valuation After Earnings Beat And Growth Guidance
TransMedics Group (TMDX) has drawn fresh attention after reporting fourth quarter and full year 2025 results that exceeded analyst expectations, along with 2026 revenue guidance and expansion plans across its transplant platform.
See our latest analysis for TransMedics Group.
After a sharp run over the past year, with a 1 year total shareholder return of 88.74%, the recent 12.30% year to date share price return and shorter term gains around the latest earnings and 2026 guidance suggest...